NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Forecast, Price & News $2.23 +0.04 (+1.83%) (As of 09/21/2023) Add Compare Share Share Today's Range$2.19▼$2.2450-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65Volume4.76 million shsAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice Target$3.58 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Paratek Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside60.3% Upside$3.58 Price TargetShort InterestHealthy6.11% of Float Sold ShortDividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews Sentiment0.85Based on 3 Articles This WeekInsider TradingSelling Shares$313,161 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector793rd out of 971 stocksBiotechnology Industry16th out of 25 stocks 3.0 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.58, Paratek Pharmaceuticals has a forecasted upside of 60.3% from its current price of $2.23.Amount of Analyst CoverageParatek Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.11% of the float of Paratek Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverParatek Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Paratek Pharmaceuticals has recently decreased by 6.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next 3.3 News and Social Media Coverage News SentimentParatek Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Paratek Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PRTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $313,161.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Paratek Pharmaceuticals (NASDAQ:PRTK) StockParatek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More PRTK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTK Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comParatek Pharmaceuticals (NASDAQ:PRTK) Now Covered by Analysts at StockNews.comSeptember 26, 2023 | americanbankingnews.comParatek Pharmaceuticals (NASDAQ:PRTK) Share Price Crosses Above 200-Day Moving Average of $2.10October 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 21, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 19, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals shareholders approve $462M buyout dealSeptember 18, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SOctober 1, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 12, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 7, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsAugust 10, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 4, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionJuly 27, 2023 | seekingalpha.comPRTK Paratek Pharmaceuticals, Inc.July 11, 2023 | finance.yahoo.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | msn.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 6, 2023 | msn.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16June 27, 2023 | msn.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalJune 27, 2023 | finance.yahoo.comEuropean Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseSee More Headlines Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Company Calendar Last Earnings8/03/2023Today10/01/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Price Target and Rating Average Stock Price Forecast$3.58 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.15 Forecasted Upside/Downside+60.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael F. Bigham CPA (Age 65)CPA, M.B.A., MBA, Exec. Chairman Comp: $954.39kDr. Evan Loh FACC (Age 64)FAHA, M.D., CEO & Director Comp: $1.14MMr. Adam Woodrow (Age 56)Pres & Chief Commercial Officer Comp: $763.51kMs. Sarah Higgins (Age 48)VP of Fin., Controller & Principal Accounting Officer Mr. William M. Haskel (Age 61)Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. Mr. Jonathan LightDeputy Gen. Counsel & Chief Compliance OfficerMs. Karen McGrathChief People OfficerMr. Randall B. Brenner (Age 50)Chief Devel. & Regulatory Officer More ExecutivesKey CompetitorsPardes BiosciencesNASDAQ:PRDSKodiak SciencesNASDAQ:KODAtara BiotherapeuticsNASDAQ:ATRACara TherapeuticsNASDAQ:CARAAffimedNASDAQ:AFMDView All CompetitorsInsiders & InstitutionsGTS Securities LLCBought 22,000 shares on 8/16/2023Ownership: 0.038%Polar Asset Management Partners Inc.Bought 479,504 shares on 8/15/2023Ownership: 0.837%XTX Topco LtdBought 62,938 shares on 8/15/2023Ownership: 0.110%Citadel Advisors LLCSold 2,800 shares on 8/15/2023Ownership: 0.000%State Street CorpSold 9,900 shares on 8/14/2023Ownership: 0.377%View All Insider TransactionsView All Institutional Transactions PRTK Stock - Frequently Asked Questions Should I buy or sell Paratek Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares. View PRTK analyst ratings or view top-rated stocks. What is Paratek Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $2.15 to $5.00. On average, they predict the company's stock price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts. How have PRTK shares performed in 2023? Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of 2023. Since then, PRTK shares have increased by 19.3% and is now trading at $2.23. View the best growth stocks for 2023 here. When is Paratek Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PRTK earnings forecast. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Thursday, August, 3rd. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. The specialty pharmaceutical company earned $39.99 million during the quarter, compared to the consensus estimate of $34.63 million. What ETF holds Paratek Pharmaceuticals' stock ? AltShares Event-Driven ET holds 17,764 shares of PRTK stock, representing 1.36% of its portfolio. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $2.23. How much money does Paratek Pharmaceuticals make? Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $127.82 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. How many employees does Paratek Pharmaceuticals have? The company employs 268 workers across the globe. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039. This page (NASDAQ:PRTK) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.